Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a<i>BRCA1</i>or<i>BRCA2</i>Mutation

Abstract

The risk of ovarian cancer among carriers of a BRCA1 or BRCA2 mutation decreases with each birth but not with increased duration of use of oral contraceptives. These data suggest that it is premature to use oral contraceptives for the chemoprevention of ovarian cancer in carriers of such mutations.